1 / 11

WP7 “Dissemination and exploitation”

WP7 “Dissemination and exploitation”. Overview and plans. Horizon 2020 Communication & Dissemination Requirements. New criteria for Communication & Dissemination: Projects need a comprehensive communication plan To ensure high visibility of the funded actions

burket
Download Presentation

WP7 “Dissemination and exploitation”

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. WP7 “Dissemination and exploitation” Overview and plans

  2. Horizon 2020 Communication & DisseminationRequirements New criteria for Communication & Dissemination: • Projects need a comprehensive communication plan • To ensure high visibility of the funded actions • To maximise the results of the impact • New Open Access Policy: • Each beneficiary has to ensure open access to all peer-reviewed scientific publications linked to the project results. • A statement and/or visual means to identify EU funding Without communication, research is not useful, For efforts to have an impact, they need to be known

  3. Partners involved EFA will lead thisWP with the support of the following Partner Organisations: • Centre for Research and Technology Hellas (CERTH) • Imperial College London (ICL) • IHP Microelectronics(IHP) • University of Patras (UPAT) • LeidenUniversityMedical Center (LUMC) • Aerocrine AB (AEROCRINE) • University of Mancester(UMAN) • Asthma UK (AUK) • ZorgGemak MedVision360 BV (MV) • AllertecHellas Pharmaceutical (Allertec) • Cnet Svenska AB (CNET)

  4. Objectives • To raise public awareness of project developments among key user groups, the scientific community and the general public • To facilitate sharing of knowledge inside the Consortium • To develop a business plan for the project outcomes • To manage Intellectual Property Rights

  5. Tasks • T7.1 Dissemination activities, material and publication (Leader: EFA) D7.1; D7.2 • T7.2 Exploitation and myAirCoach Business models (Leader: AEROCRINE) D7.3 • T7.3 IPR management (Leader: Allertec) D7.4 • T7.4Standardization and concertation actions (Leader: CERTH) D7.5

  6. Deliverables • D7.1 Dissemination Plan and myAirCoach dissemination material (M3, M12, M24, M36, PU, Report) • D7.2 Project Web Presence (Website, Wiki, Blog, Social Media) (M3, PU, Report + Prototype) • D7.3 Exploitation Report and myAirCoach Business models (M24 preliminary, M36 final version, RE, Report) • D7.4 IPR Protection Plan (M12 preliminary, M24 final version, RE, Report) • D7.5 Standardisation and concertation activities report (M24 preliminary, M36 final version, PU, Report) • D7.6 Data Management Plan (M6, updated at M24 and M36, PU, R+s/w)

  7. Milestones and indicators Milestones: • M1: Web site available • M12: Definition of exploitation scenarios. Signature of Exploitation Agreement • M13:Business plan and market analysis available Key success indicators: • Dissemination material, including the web-site, are available. myAirCoach market analysis and business plan highlights the major myAirCoach developments. • Concertationactivities with other projects and initiatives with similar objectives have resulted in benefit for all involved parties and new joint initiatives

  8. What to communicate • Objectives, strategic relevance and key facts • News regardingachievements and results • Events promotion and eventsresults • System’sfindingsthatcan help and support patients Project outputs to bedisseminated: • Ready for use solutions (Vitualcommunityplatform, patient guidance platform) • Models, information, lessonslearned and recommendations

  9. To whom to communicate • Clinicians • Practitioners in hospitals • Political institutions • Members of EU Commission • Nongovernmentalorganizations • National and international scientists • Participants of the myAirCoach test campaigns • Researchers and staff involved in myAirCoach • Schools and othereducational institutions • General public • Industry, pharmaceuticalcompanies, medical providers Mobile Network operators, SMEs in the medical area, Health service providers

  10. Exploitation • Academic and researchorganizations: • Direct exploitationby protecting the knowledge created and by granting licenses for its use • Indirect exploitationby increasing the leadership in the respective areas of research • Industrialpartners (SMEs): • Direct exploitation of technicaldevelopments • Indirect exploitation by leveraging potential business strengths through the association with other partners • End user authorities: through EFA and AUK members

  11. Thank you for your attention! European Federation of Allergy and Airways Diseases Patients' Associations  (EFA) EFA 35 Rue du Congrès 1000 Brussels, Belgium www.efanet.org

More Related